Related Experiment Video
Updated: Aug 3, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Biology and management of idiopathic myelofibrosis
1Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA. smithd@jhmi.edu
Abstract:
Idiopathic myelofibrosis (IMF) is a hematopoietic stem cell disorder characterized by hypercellularity of the bone marrow with an increase in abnormal megakaryocytes, varying degrees of marrow fibrosis, and extramedullary hematopoiesis. The central lesion of the IMF stem cell is not known; however, the marrow fibrosis is a polyclonal reaction to inflammatory mediators generated by the transformed clone. Historical management approaches have centered on improving the patient's blood counts in a palliative manner. Recent reports of autologous and allogeneic bone marrow transplantation (BMT) in IMF patients indicate that stable engraftment occurs easily, the marrow fibrosis is a reversible process, and a graft-versus-fibrosis effect may exist. The goals of future therapies will target marrow fibrosis and harness the graft-versus-fibrosis effect to safely and effectively treat patients with IMF.
Related Concept Videos
Types of Intermediate Filaments
Differentiation of Common Myeloid Progenitor Cells
Introduction to Fibroblasts
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Myocarditis III: Medical Management

